Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
In this research project, we investigated the usefulness of radionuclide therapy using 225Ac-DOTA-RGD2 for pancreatic cancers with αvβ3 integrin. A biodistribution study of 111In-DOTA-RGD2 revealed high uptake in tumors and kidneys. In a therapeutic experiment, 225Ac-DOTA-RGD2 significantly inhibited tumor growth. However, liver toxicity was found partly.
|